

# **Coronary Drug Eluting Stent Market - Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035**

<https://marketpublishers.com/r/C0CFE9BDBBAFEN.html>

Date: April 2022

Pages: 254

Price: US\$ 4,799.00 (Single User License)

ID: C0CFE9BDBBAFEN

## **Abstracts**

The coronary drug eluting stent market is currently valued at \$3.8 billion in 2022 and is anticipated to experience a compounded annual growth rate (CAGR) of 9.26% throughout the forecast period. Cardiovascular diseases (CVD) constitute a prominent global health challenge, ranking among the primary causes of mortality worldwide, outpacing conditions such as cancer and respiratory disorders. The World Health Organization (WHO) reports that cardiac disorders are responsible for approximately one-third of the annual global deaths, totaling an estimated 18 million fatalities. Notably, coronary artery disease (CAD) stands out as the most prevalent form of cardiovascular disorder, contributing to around 11 million deaths in 2020. The onset of the pandemic in the same year resulted in a notable over 3% increase in deaths attributed to heart diseases.

According to the Centers for Disease Control and Prevention (CDC), the economic impact associated with cardiovascular diseases, encompassing annual medical costs and productivity loss, is anticipated to exceed \$1,000 billion by 2030. Addressing the critical consequences of vessel narrowing and plaque accumulation in arteries involves the utilization of various coronary interventional devices. Among these, coronary drug-

eluting stents (DES) have emerged as a favored solution.

Traditionally, bare-metal stents (BMS) were extensively employed to open blocked passages and restore proper blood flow to the heart. However, a shift in preference has been witnessed in recent years, with an increasing inclination towards drug-eluting stents (DES). These stents are coated with a polymer containing an antiproliferative drug, showcasing effectiveness in reducing or preventing in-stent restenosis, a significant complication associated with bare-metal stents. Considered revolutionary in interventional cardiology, cardiac stents enhance revascularization rates and diminish the risk of thrombosis.

Currently, the market offers more than 90 cardiovascular drug-eluting stents from approximately 40 global players, with the majority utilizing metals like platinum chromium and stainless steel. Notably, patents in this domain have experienced a compound annual growth rate (CAGR) of 13% over the past two decades. Innovations in cardiovascular therapeutics have been remarkable, including the development of advanced bioresorbable stents, drug combinations, and polymer and nanomaterial coatings aimed at improving safety and efficacy. Noteworthy is a recent proposal for an implantable biocompatible stent with miniaturized ultrasonic transducers for real-time monitoring of restenosis.

Moreover, recent strides in augmented reality and deep learning have the potential to facilitate the creation of patient-specific stents, paving the way for personalized treatment for individuals with cardiovascular disorders. Given the ongoing pace of innovation in the coronary drug-eluting stent market, coupled with the adoption of cutting-edge technologies by device developers, the increasing incidence of heart diseases, and the growing demand for related treatments, substantial growth is anticipated in the cardiovascular drug-eluting stent market during the forecast period.

## Key Market Segments

### Type of Drug Eluted

Sirolimus

Paclitaxel

Everolimus

Zotarolimus

Others

#### Stent Material

Platinum Chromium

Cobalt Chromium

Stainless Steel

Others

#### Geographical Regions

North America

Europe

Asia-Pacific

MENA

Latin America

Rest of the World

#### Research Coverage:

The report studies the coronary drug eluting stent market by type of drug eluted, stent material and key geographical regions.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to major regions.

A comprehensive overview of companies engaged in the development and manufacturing of cardiovascular drug eluting stents, including details on their establishment year, company size, product range, and headquarters location. Additionally, an assessment of over 90 cardiovascular drug eluting stents based on parameters like eluted drug type, stent material, and various technical specifications.

In-depth market trend analysis using five visual representations, including a heat map based on drug type and concentration, a stacked bar chart for drug and stent material, a tree map for stent dimensions, a 4D bubble chart comparing industry players, and a grid analysis based on multiple parameters.

Company competitiveness analysis for cardiovascular drug eluting stent developers considering experience years and portfolio strength encompassing product variety, stent attributes, and more.

Detailed profiles of prominent players in cardiovascular drug eluting stents, covering company background, employee count, headquarters location, executive team members, and their cardiovascular drug delivery device portfolio, along with recent developments and future prospects.

An in-depth analysis of patents related to cardiovascular drug eluting stents, categorized by type, publication year, location, CPC symbols, applicant types, and leading industry/non-industry players, featuring three-dimensional bubble analysis, patent benchmarking, and valuation.

A case study focusing on novel cardiovascular therapeutics and solutions, providing details about the developers, establishment years, company sizes, and headquarters locations.

An extensive analysis estimating the current and future demand for cardiovascular drug eluting stents, based on parameters like eluted drug type,

stent material, and geographical regions for the years 2022-2035, considering factors like the number of patients with cardiovascular disorders and average stent prices in different regions.

### Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.

### Key Market Companies

Alvimedica

B. Braun

Boston Scientific

Cook Medical

Eurocor Scientific

Lepu Medical

Medtronic

Meril

Relisys

Sahajanand Medical Technologies

## Contents

### 1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

### 2. EXECUTIVE SUMMARY

### 3. INTRODUCTION

- 3.1 Chapter Overview
- 3.2. Overview of Cardiovascular Drug Delivery Devices
  - 3.2.1. Types of Cardiovascular Drug Delivery Devices
    - 3.2.1.1. Drug Eluting Stents (DES)
    - 3.2.1.2. Drug Eluting Balloons (DEB)
- 3.3. Key Indications Targeted by Cardiovascular Drug Delivery Devices
  - 3.3.1. Atherosclerosis
  - 3.3.2. Heart Failure
  - 3.3.3. In-Stent Restenosis
- 3.4. Potential Risks Associated with Drug Eluting Stents and Balloons
- 3.5. Recent Advancements Related to Cardiovascular Drug Delivery Devices
- 3.6. Concluding Remarks

### 4. MARKET LANDSCAPE

- 4.1. Chapter Overview
- 4.2. Novel Cardiovascular Drug Delivery Devices: Overall Market Landscape
  - 4.2.1. Analysis by Type of Drug Eluted
  - 4.2.2. Analysis by Stent Material
  - 4.2.3. Analysis by Maximum Post Dilatation Limit
  - 4.2.4. Analysis by Maximum and Minimum Stent Length
  - 4.2.5. Analysis by Maximum and Minimum Stent Diameter
  - 4.2.6. Analysis by Maximum Nominal Pressure
  - 4.2.7. Analysis by Maximum Rated Burst Pressure
  - 4.2.8. Analysis by Administered Drug Concentration
  - 4.2.9. Analysis by Minimum Strut Thickness

#### 4.3. Novel Cardiovascular Drug Delivery Devices: Developers Landscape

- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Leading Players: Analysis by Number of Products

### 5. KEY INSIGHTS

#### 5.1. Chapter Overview

#### 5.2. Analysis by Eluted Drug and Administered Drug Concentration (Heat Map)

#### 5.3. Analysis by Eluted Drug and Stent Material (Stacked Bar Chart)

#### 5.4. Analysis by Maximum Stent Length and Maximum Stent Diameter (Tree Map)

#### 5.5. Analysis by Year of Establishment, Company Size, Number of Products Offered and Region (4D Bubble Chart)

#### 5.6. Analysis by Company Size, Region, Number of Products Offered, Maximum Stent Length and Maximum Stent Diameter (Grid Representation)

### 6. COMPANY COMPETITIVENESS

#### 6.1. Chapter Overview

#### 6.2. Key Assumptions and Parameters

#### 6.3. Methodology

##### 6.3.1. Company Competitiveness Analysis: Small Companies

##### 6.3.2. Company Competitiveness Analysis: Mid-sized Companies

##### 6.3.3. Company Competitiveness Analysis: Large Companies

##### 6.3.4. Company Competitiveness Analysis: Very Large Companies

### 7. COMPANY PROFILES

#### 7.1. Chapter Overview

#### 7.2. Alvimedica

##### 7.2.1. Company Overview

##### 7.2.2. Novel Cardiovascular Drug Delivery Device Portfolio

##### 7.2.3. Recent Developments and Future Outlook

#### 7.3. B. Braun

##### 7.3.1. Company Overview

##### 7.3.2. Novel Cardiovascular Drug Delivery Device Portfolio

##### 7.3.3. Recent Developments and Future Outlook

#### 7.4. Boston Scientific



- 7.4.1. Company Overview
- 7.4.2. Novel Cardiovascular Drug Delivery Device Portfolio
- 7.4.3. Recent Developments and Future Outlook
- 7.5 Cook Medical
  - 7.5.1. Company Overview
  - 7.5.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.5.3. Recent Developments and Future Outlook
- 7.6. Eurocor Scientific
  - 7.6.1. Company Overview
  - 7.6.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.6.3. Recent Developments and Future Outlook
- 7.7. Lepu Medical
  - 7.7.1. Company Overview
  - 7.7.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.7.3. Recent Developments and Future Outlook
- 7.8. Medtronic
  - 7.8.1. Company Overview
  - 7.8.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.8.3. Recent Developments and Future Outlook
- 7.9. Meril
  - 7.9.1. Company Overview
  - 7.9.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.9.3. Recent Developments and Future Outlook
- 7.10. Relisys
  - 7.10.1. Company Overview
  - 7.10.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.10.3. Recent Developments and Future Outlook
- 7.11. Sahajanand Medical Technologies
  - 7.11.1. Company Overview
  - 7.11.2. Novel Cardiovascular Drug Delivery Device Portfolio
  - 7.11.3. Recent Developments and Future Outlook

## **8. PATENT ANALYSIS**

- 8.1. Chapter Overview
- 8.2. Scope and Methodology
- 8.3. Novel Cardiovascular Drug Delivery Devices: Patent Analysis
  - 8.3.1. Analysis by Type of Patent
  - 8.3.2. Analysis by Publication Year

- 8.3.3. Analysis of Granted Patents by Publication Year
- 8.3.4. Analysis by Filed Patent by Publication Year
- 8.3.5. Analysis by Patent Publication Year and Type of Player
- 8.3.6. Analysis by Issuing Authority
- 8.3.7. Analysis by Patent Focus
- 8.3.8. Analysis by Patent Age
- 8.3.9. Analysis by CPC Symbols
- 8.3.10. Leading Players: Analysis by Number of Patents
- 8.3.11. Leading Inventors: Analysis by Number of Patents
- 8.4. Novel Cardiovascular Drug Delivery Devices: Patent Benchmarking Analysis
  - 8.4.1. Analysis by Patent Characteristics
- 8.5. Novel Cardiovascular Drug Delivery Devices: Patent Valuation Analysis

## **9. CASE STUDY: NOVEL CARDIOVASCULAR THERAPEUTICS AND SERVICES / SOLUTIONS**

- 9.1. Chapter Overview
- 9.2. Novel Cardiovascular Therapeutics: Overall Market Landscape
  - 9.2.1. Novel Cardiovascular Therapeutics Developers: Distribution by Year of Establishment
  - 9.2.2. Novel Cardiovascular Therapeutics Developers: Distribution by Company Size
  - 9.2.3. Novel Cardiovascular Therapeutics Developers: Distribution by Location of Headquarters
  - 9.2.4. Novel Cardiovascular Therapeutics Developers: Distribution by Type of Therapy
  - 9.2.5. Novel Cardiovascular Therapeutics Developers: Distribution by Phase of Development
  - 9.2.6. Novel Cardiovascular Therapeutics: Gene Therapy
  - 9.2.7. Novel Cardiovascular Therapeutics: Next Generation Complement Therapeutics
  - 9.2.8. Novel Cardiovascular Therapeutics: Oral Proteins and Peptides Therapies
  - 9.2.9. Novel Cardiovascular Therapeutics: Regulatory T-cell (Tregs) Therapies
  - 9.2.10. Novel Cardiovascular Therapeutics: Subcutaneous Biologics
- 9.3. Novel Cardiovascular-based Services / Solutions: Overall Market Landscape
  - 9.3.1. Novel Cardiovascular-based Service Providers: Distribution by Year of Establishment
  - 9.3.2. Novel Cardiovascular-based Service Providers: Distribution by Company Size
  - 9.3.3. Novel Cardiovascular-based Service Providers: Distribution by Location of Headquarters
  - 9.3.4. Novel Cardiovascular-based Service Providers: Distribution by Type of Service
  - 9.3.5. Novel Cardiovascular-based Services: Biopharmaceutical Contract Research

## Services

9.3.6. Novel Cardiovascular-based Solutions: Digital Therapeutics Solutions

9.3.7. Novel Cardiovascular-based Solutions: Precision Medicine Software

## 10. DEMAND ANALYSIS

### 10.1. Chapter Overview

### 10.2. Key Assumptions and Methodology

### 10.3. Global Demand for Novel Cardiovascular Drug Delivery Devices, 2022-2035

#### 10.3.1. Analysis by Type of Drug Eluted

10.3.1.1. Global Demand for Sirolimus Eluting Stents

10.3.1.2. Global Demand for Paclitaxel Eluting Stents

10.3.1.3. Global Demand for Everolimus Eluting Stents

10.3.1.4. Global Demand for Zotarolimus Eluting Stents

10.3.1.5. Global Demand for Other Drug Eluting Stents

#### 10.3.2. Analysis by Stent Material

10.3.2.1. Global Demand for Platinum Chromium Stents

10.3.2.2. Global Demand for Cobalt Alloy Stents

10.3.2.3. Global Demand for Stainless Steel Stents

10.3.2.4. Global Demand for Stents Based on Other Materials

#### 10.3.3. Analysis by Geography

10.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in North America

10.3.3.1.1. Demand for Novel Cardiovascular Drug Delivery Devices in the US

10.3.3.1.2. Demand for Novel Cardiovascular Drug Delivery Devices in Canada

10.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in Europe

10.3.3.2.1. Demand for Novel Cardiovascular Drug Delivery Devices in France

10.3.3.2.2. Demand for Novel Cardiovascular Drug Delivery Devices in Germany

10.3.3.2.3. Demand for Novel Cardiovascular Drug Delivery Devices in Italy

10.3.3.2.4. Demand for Novel Cardiovascular Drug Delivery Devices in the

#### Netherlands

10.3.3.2.5. Demand for Novel Cardiovascular Drug Delivery Devices in Spain

10.3.3.2.6. Demand for Novel Cardiovascular Drug Delivery Devices in the UK

10.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Asia

10.3.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in China

10.3.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in India

10.3.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Japan

10.3.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in South Korea

10.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in Middle East and North Africa

- 10.3.3.4.1. Demand for Novel Cardiovascular Drug Delivery Devices in Israel
- 10.3.3.4.2. Demand for Novel Cardiovascular Drug Delivery Devices in Turkey
- 10.3.3.5. Demand for Novel Cardiovascular Drug Delivery Devices in Latin America
  - 10.3.3.5.1. Demand for Novel Cardiovascular Drug Delivery Devices in Brazil
- 10.3.3.6. Demand for Novel Cardiovascular Drug Delivery Devices in Rest of the World
  - 10.3.3.6.1. Demand for Novel Cardiovascular Drug Delivery Devices in Australia
  - 10.3.3.6.2. Demand for Novel Cardiovascular Drug Delivery Devices in New Zealand

## 11. MARKET FORECAST

- 11.1. Chapter Overview
- 11.2. Key Assumptions and Methodology
- 11.3. Global Novel Cardiovascular Drug Delivery Devices Market, 2022-2035
  - 11.3.1. Analysis by Type of Drug Eluted
    - 11.3.1.1. Global Sirolimus Eluting Stents Market
    - 11.3.1.2. Global Paclitaxel Eluting Stents Market
    - 11.3.1.3. Global Everolimus Eluting Stents Market
    - 11.3.1.4. Global Zotarolimus Eluting Stents Market
    - 11.3.1.5. Global Other Drug Eluting Stents Market
  - 11.3.2. Analysis by Stent Material
    - 11.3.2.1. Global Platinum Chromium Stents Market
    - 11.3.2.2. Global Cobalt Alloy Stents Market
    - 11.3.2.3. Global Stainless Steel Stents Market
    - 11.3.2.4. Global Market for Stents Based on Other Materials
  - 11.3.3. Analysis by Geography
    - 11.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in North America
      - 11.3.3.1.1. Novel Cardiovascular Drug Delivery Devices Market in the US
      - 11.3.3.1.2. Novel Cardiovascular Drug Delivery Devices Market in Canada
    - 11.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in Europe
      - 11.3.3.2.1. Novel Cardiovascular Drug Delivery Devices Market in France
      - 11.3.3.2.2. Novel Cardiovascular Drug Delivery Devices Market in Germany
      - 11.3.3.2.3. Novel Cardiovascular Drug Delivery Devices Market in Italy
      - 11.3.3.2.4. Novel Cardiovascular Drug Delivery Devices Market in the Netherlands
      - 11.3.3.2.5. Novel Cardiovascular Drug Delivery Devices Market in Spain
      - 11.3.3.2.6. Novel Cardiovascular Drug Delivery Devices Market in the UK
    - 11.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Asia
      - 11.3.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in China

- 11.3.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in India
- 11.3.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Japan
- 11.3.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in South Korea
- 11.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in Middle East and North Africa
  - 11.3.3.4.1. Novel Cardiovascular Drug Delivery Devices Market in Israel
  - 11.3.3.4.2. Novel Cardiovascular Drug Delivery Devices Market in Turkey
- 11.3.3.5. Novel Cardiovascular Drug Delivery Devices Market in Latin America
  - 11.3.3.5.1. Novel Cardiovascular Drug Delivery Devices Market in Brazil
- 11.3.3.6. Novel Cardiovascular Drug Delivery Devices Market in Rest of the World
  - 11.3.3.6.1. Novel Cardiovascular Drug Delivery Devices Market in Australia
  - 11.3.3.6.2. Novel Cardiovascular Drug Delivery Devices Market in New Zealand

## **12. CONCLUSION**

## **13. EXECUTIVE INSIGHTS**

- 13.1. Chapter Overview
- 13.2. Scitech Medical
  - 13.2.1. Company Snapshot
  - 13.2.2. Interview Transcript: Luciano Curado, Chief Technology Officer
- 13.3. Translumina
  - 13.3.1. Company Snapshot
  - 13.3.2. Interview Transcript: Harish Rawat, Production Executive

## **14. APPENDIX I: TABULATED DATA**

## **15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS**

## I would like to order

Product name: Coronary Drug Eluting Stent Market - Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

Product link: <https://marketpublishers.com/r/C0CFE9BDBBAFEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0CFE9BDBBAFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970